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The nuclear receptor coactivator amplified in breast
cancer 1 (AIB1/SRC-3) has a well-defined role in ste-
roid and growth factor signaling in cancer and nor-
mal epithelial cells. Less is known about its function
in stromal cells, although AIB1/SRC-3 is up-regulated
in tumor stroma and may, thus, contribute to tumor
angiogenesis. Herein, we show that AIB1/SRC-3 deple-
tion from cultured endothelial cells reduces their pro-
liferation and motility in response to growth factors
and prevents the formation of intact monolayers with
tight junctions and of endothelial tubes. In AIB1/SRC-
3/ and / mice, the angiogenic responses to sub-
cutaneous Matrigel implants was reduced by two-
thirds, and exogenously added fibroblast growth
factor (FGF) 2 did not overcome this deficiency. Fur-
thermore, AIB1/SRC-3/ and / mice showed simi-
larly delayed healing of full-thickness excisional skin
wounds, indicating that both alleles were required for
proper tissue repair. Analysis of this defective wound
healing showed reduced recruitment of inflammatory
cells and macrophages, cytokine induction, and met-
alloprotease activity. Skin grafts from animals with
different AIB1 genotypes and subsequent wounding
of the grafts revealed that the defective healing was
attributable to local factors and not to defective bone
marrow responses. Indeed, wounds in AIB1/ mice
showed reduced expression of FGF10, FGFBP3,
FGFR1, FGFR2b, and FGFR3, major local drivers of
angiogenesis. We conclude that AIB1/SRC-3 modu-
lates stromal cell responses via cross-talk with the
FGF signaling pathway. (Am J Pathol 2012, 180:
1474–1484; DOI: 10.1016/j.ajpath.2011.12.032)
1474AIB1 is the third member of the nuclear coactivator or
p160 steroid receptor coactivator (SRC-3) family that pro-
motes transcriptional activity of multiple nuclear recep-
tors, such as the estrogen receptor,1 and other transcrip-
tion factors, including E2F-1, AP-1, NFB, and STAT6.2–5
AIB1/SRC-3 has also been shown to be important in a
diverse set of growth factor signaling pathways, such as
insulinlike growth factor 1 and growth hormone signaling in
normal mouse fibroblasts and hepatocytes,6 insulinlike
growth factor 1 in breast cancer epithelium,7 and epidermal
growth factor and human epidermal growth factor receptor
2 (HER2) signaling in cancer epithelial cells.8,9 Multiple
studies have shown that the AIB1 gene is amplified and
overexpressed in breast10 and other human1,11–15 cancers.
High levels of AIB1 mRNA or protein predict significantly
worse prognosis and overall survival in patients with breast
cancer.10 Animal models corroborate the role of AIB1 as an
oncogene since expression of AIB1 under the control of
mouse mammary tumor virus in transgenic mice induced
mammary hyperplasia and tumors.16,17 Complementary to
this, AIB1 knockout in mice prevented HER2 oncogene or
carcinogen-induced mammary carcinogenesis.9,18
Although the coactivators in the SRC family are thought
of mainly as oncogenes that affect epithelial responses to
external hormone, growth factor, and cytokine sig-
nals,10,19 analysis of recently published human cancer
expression array data20,21 reveals significant increases in
AIB1/SRC-3 expression in the stromal compartment of
breast cancers (see Supplemental Figure S1 at http://
ajp.amjpathol.org), suggesting a potential role of AIB1
expression in the stromal response during malignant pro-
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was also suggested from reduced angiogenesis in mam-
mary and thyroid tumors in AIB1/SRC-3 knockout mice.9,22
At the cellular and molecular levels, there are many
parallels between a healing wound and processes ongo-
ing in the tumor and surrounding stroma.23 Some 150
years ago, Rudolf Virchow (1863)24 viewed tissue injury
and repair as part of the malignant process, and tumors
have been described as “wounds that will not heal.”25 An
important component of wound healing is the formation of
new blood vessels that is controlled by a well-orches-
trated set of different drivers that can be dysregulated in
tumors.26–28 To address the contribution of AIB1/SRC-3
to stromal responses, we assessed the impact of AIB1/
SRC-3 depletion on endothelial cell function in vitro and
evaluated the effect on neoangiogenesis and wound
healing in AIB1/SRC-3 knockout animals. In addition, ex-
cisional wound healing in full-thickness skin transplants
from and into different AIB1/SRC-3 genotype animals were
used to distinguish between local and systemic factors. We
found that AIB1/SRC-3 has a major role in the local control
of wound healing, affecting different aspects of the stromal
response and major drivers in the fibroblast growth factor
(FGF) signaling pathway, ie, FGF10, FGFBP3, FGFR1,
FGFR2b, and FGFR3. It is striking that AIB1/SRC-3 is up-
regulated not only in tumor stroma but also in healing
wounds, suggesting a broader role in stromal function.
Materials and Methods
Cell Lines
Primary human umbilical vein endothelial cells (HUVECs)
were maintained in endothelial basal medium-2 (Lonza Inc.,
Walkersville, MD) supplemented with 2% fetal bovine serum
as recommended by the supplier. AIB1/SRC-3/ mouse
embryonic fibroblasts,29 NIH3T3, and human foreskin fi-
broblasts (Hs-27) were grown in Dulbecco’s modified
Eagle’s medium (Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum.
Short Hairpin RNA Constructs and Lentivirus
Infection
Control scrambled short hairpin RNA (shRNA)30 was pur-
chased from Addgene (Cambridge, MA). AIB1 shRNA #1
(5=-TGGTGAATCGAGACGGAAACA-3=) and #2 (5=-GCA-
GTCTATTCGTCCTCCATA-3=)29 were subcloned into the
EcoRI and AgeI restriction sites in PLKO.1 puro (Addgene).
Lentivirus production was performed as described else-
where31 using the recommended protocols for production
of lentiviral particles with packaging plasmid (pCMV-dR8.2
dvpr) and envelope plasmid (pCMV-VSVG) (Addgene).
Tube Formation Assay
HUVECs infected with control or AIB1/SRC-3 shRNA len-
tivirus for 48 hours were plated in Matrigel (BD Biosci-
ences, Franklin Lakes, NJ)-coated 8-well chamber slides
(3  105 cells per well) as described.32 Tube formationwas imaged, and tube diameters were quantitated at 18
hours using NIH ImageJ software.
Monolayer Formation Assay
Control or AIB1/SRC-3 shRNA-infected HUVECs (2  105)
were plated in wells of the electric cell-substrate impedance
sensor system (8W10E; Applied BioPhysics, Troy, NY).
Analysis of the monolayer was performed after 20 hours.
Details are provided in studies by Wellstein and col-
leagues.33,34
Cell Migration Assay
A denuded area in control or AIB1/SRC-3 shRNA-infected
HUVEC confluent monolayers was generated by scraping
with a micropipette tip. The extent of migration was deter-
mined in the presence or absence of mitomycin C (2 g/
mL) (Sigma-Aldrich, St. Louis, MO) by measuring the dis-
tance between the migration fronts at 0, 24, and 48 hours.
Quantification from five independent digitized images was
performed using NIH ImageJ software. Control and shRNA-
infected Hs-27 cells were plated in 12-well plates. Cell cul-
ture inserts to generate 0.5-mm-diameter, rectangular, cell-
free spaces (ibidi GmbH, Martinsried, Germany) were
placed into the wells and then were removed after 24 hours.
Time-lapse phase-contrast microscopy (Nikon Eclipse
TE300 inverted microscope system; Nikon, Melville, NY)
was used to continuously capture images and follow migra-
tion at different time points to calculate migration rates.
Proliferation Assays
One thousand control or AIB1/SRC-3 shRNA-infected
HUVECs were plated in 96-well plates. Cell proliferation
was measured at 24, 48, and 72 hours using CellTiter-Glo
(Promega, Madison, WI) according to the manufacturer’s
instructions. Alternatively, cells were stained with crystal
violet (0.52% crystal violet in 25% methanol). After wash-
ing the cells to remove excess stain, the plates were
dried and the bound stain was solubilized by the addition
of 100 L of 100 mmol/L sodium citrate in 50% ethanol.
Staining intensity, which is proportional to cell number,
was then determined by measuring absorbance at 570
nm using a 96-well plate reader.
Apoptosis Assay
Apoptosis in control or AIB1/SRC-3 shRNA-infected HUVECs
(2  105 cells) was determined by annexin V–fluorescein
isothiocyanate staining (Trevigen, Gaithersburg, MD) ac-
cording to the manufacturer’s instructions 48 hours after
infection.
Studies in Animals
The generation of mice with different AIB1/SRC-3 geno-
types (/, /, and /) is as previously described.9
Animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee.
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Growth factor–depleted Matrigel (0.5 mL) without and
with FGF2 (10 g/mL) was injected subcutaneously into
3- to 4-month-old mice. Five days later, the Matrigel plugs
were harvested, and 5-m sections of formalin-fixed, par-
affin-embedded sections were stained with H&E. The
number of endothelial cell nuclei was counted in 10 ran-
dom fields at 40 magnification.
Wound-Healing Assay
A 3-mm-diameter dermal biopsy punch (Miltex Inc., Beth-
page, NY) was used to generate four full-thickness skin
wounds through the skin and panniculus carnosus mus-
cle in anesthetized animals (3- to 4-month-old males),
and they were left to heal. After wounding, the animals
were euthanized, and wounded tissues were harvested
at the times indicated. Histologic sections were cut rect-
angular to the skin surface across the wound. Serial par-
affin-embedded tissue sections (5 m) were stained with
H&E and were analyzed by three observers blinded to
the design. Photographs of open wound areas at different
times (1 to 8 days) after injury were quantified using NIH
ImageJ software. The distance between the epithelial tips
was measured in day 5 wound microphotographs using
NIH ImageJ software and the following formula: (Wound
Diameter  Length of Epithelial Tongues).
Immunohistochemical Analyses
Immunohistochemical analyses for proliferating cell nu-
clear antigen (PNCA; Sigma-Aldrich), F4/80 (AbD Sero-
tec, Raleigh, NC), vascular endothelial growth factor-A
Table 1. Primers Used for Quantitative Real-Time PCR Analysis o
Gene Forward primer
CD105 5=-TTTGTACCCACAACAGGTCTCGC
Thy1 5=-AGCCAACTTCACCACCAAGGATG
Bst1 5=-TGCGACGTGCTGTATGGCAAAGT
CD14 5=-ACATCTTGAACCTCCGCAACGTG
CD16 5=-TTGCAGTGGACACGGGCCTTTAT
CD133 5=-AAGATGCAGCCACCCAGCTCAAT
CD31 5=-AGCTAGCAAGAAGCAGGAAGGAC
CD34 5=-CCATTTCTCCTCTCTCGCCTCTT
CD45 5=-GGGTTGTTCTGTGCCTTGTT-3=
F4/80 5=-GGGACAAACACTTGGTGGTGTGA
FGF7 5=-GAACAGCTACAACATCATGGAAA
FGF10 5=-GCCTCAGCCTTTCCCCAC-3=
FGFBP1 5=-GAGGCAGCCTGAAGTCTC-3=
FGFBP3 5=-AGCCCTTGCTAGTGAAGTCCAAC
FGFR1 5=-GTAGCTCCCTACTGGACATCC-3
FGFR2 5=-TGCCCTACCTCAAGGTCCTG-3=
FGFR3 5=-CCTCAGGAGATGACGAAGATGGG
FGFR4 5=-ATGACCGTCGTACACAATCTTAC
FGFR1b 5=-TACGCTTGCGTGACCAGCAGC-3
FGFR1c 5=-ACGGACAACACCAAACCAAACCC
FGFR2b 5=-TAGCTCCAATGCAGAAGTGCTGG
FGFR2c 5=-GCCCGGCCCTCCTTCAGTTTAG-
FGFR3b 5=-GCGATGCACAGCCACACATCCA-
FGFR3c 5=-GAGACGGAGCCGCGCGTGTC-3=
mAIB1 5=-AGTGGACTAGGCGAAAGCTCT-3(VEGF-A; Santa Cruz Biotechnology, Santa Cruz, CA),and AIB1 (Cell Signaling Technology, Danvers, MA) were
performed on wound sections as previously de-
scribed.9,35 F4/80, VEGF-A, and proliferating cell nuclear
antigen–positive cells were counted in 5 to 10 nonover-
lapping visual fields.
Quantitative Real-Time PCR
Total RNA from wounded tissues and bone marrow was
extracted using the RNeasy fibrous mini kit and RNeasy
mini kit (Qiagen, Valencia, CA), respectively, according
to the manufacturer’s instructions. cDNA was synthe-
sized using the iScript cDNA synthesis kit (Bio-Rad Lab-
oratories, Hercules, CA) according to the manufactur-
ers’s protocol. Quantitative real-time PCR was performed
in an iCycler iQ (Bio-Rad Laboratories) using the iQ SYBR
green supermix (Bio-Rad Laboratories) under the follow-
ing conditions: 95°C for 3 minutes followed by 40 cycles
(95°C for 20 seconds, 60°C for 30 seconds, and 72°C for
40 seconds). PCR primers are listed in Table 1.
In Vivo Fluorescence Imaging
A broad-range fluorescence activatable substrate (2
nmol) (MMPsense 750 FAST; PerkinElmer, Waltham, MA)
for matrix metalloproteases (MMPs) 2, 3, 7, 9, 12, and 13
that is optically silenced on injection was injected into the
mouse tail vein 1 day after wounding. In vivo fluorescence
imaging was performed on days 2 through 8 after wound-
ing using a Maestro in vivo imaging system (PerkinElmer)
(excitation wavelength  641 to 681 nm, emission wave-
length  700 to 950 nm). Spectral analysis of the images
was conducted using the Maestro software by unmixing
the pure spectrum of the agent from the autofluorescence
ling Molecules in Wounds
Reverse primer
5=-AACGTGGACTTCACGCACAGCATT-3=
5=-GCCACACTTGACCAGCTTGTCTCTAT-3=
5=-TTCCAATAGGAGTCCACGGCGTTGTT-3=
5=-TTGAGCGAGTGTGCTTGGGCAATA-3=
5=-TTGTCTTGAGGAGCCTGGTGCTTT-3=
5=-ATGCTATCGCAGATCTTGCTGGCT-3=
5=-TAAGGTGGCGATGACCACTCCAAT-3=
5=-AGTTTCCTGGGAAGAAGTGGTAGC-3=
5=-GGATAGATGCTGGCGATGAT-3=
5=-CCTGGGCCTTGAAAGTTGGTTTGT-3=
5=-CATAGAGTTTCCCTTCCTTGTTC-3=
5=-CTTGGCAGGTGACAGGGAAC-3=
5=-GGAGTCTCATCACGTCAGC-3=
5=-TAGGTCTCAGTGAGCTCGGCATT-3=
5=-GCATAGCGAACCTTGTAGCCTC-3=
5=-TAGAATTACCCGCCAAGCAC-3=
5=-GCAGTTTCTTATCCATTCGCTCCG-3=
5=-TGTCCAGTAGGGTGCTTGC-3=
5=-CTACAGGCCTACGGTTTGGTTTGG-3=
5=-GGTGTCCCACTCGACGGGCA-3=
5=-AGGCGCTTGCTGTTTGGGCAG-3=
5=-TAGTCCAACTGATCACGGCGGC-3=
5=-GTGCGTCTGCCTCCACATTCTCACT-3=
5=-ACGCAGGCCGGGACTACCATG-3=
5=-GTTGTCGATGTCGCTGAGATTT-3=f Signa
A-3=
A-3=
T-3=
T-3=
T-3=
A-3=
A-3=
CA-3=
A-3=
-3=
T-3=
=
-3=
-3=
=
TG-3=
C-3=
3=
3=of the mice before injection. The fluorescence signal of
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among the four wounds.
Western Blot Analysis
Western blot analysis was performed as described else-
where.7 Western blot analyses for AIB1, phospho–mito-
gen-activated protein kinase, mitogen-activated protein ki-
nase, phospho-Akt, Akt, phospho-p38, and p38 (Cell
Signaling Technology) were performed with the respective
rabbit polyclonal antibodies. Immunoblot analyses for hu-
man actin were performed using a respective mousemono-
clonal antibody (Chemicon International, Temecula, CA).
Expression Analysis
The expression profile of 84 angiogenesis-related genes
was determined using a 96-well format mouse angiogen-
esis RT2 Profiler PCR array (SABiosciences, Frederick,
MD) according to the manufacturer’s instructions. Purifi-
cation of total RNA prepared from 4-day wounds and cDNA
preparation are described in Quantitative Real-Time PCR.
Quantitative PCRwas performed using the RT2 SYBR green
quantitative PCR master mixes (SABiosciences).
Skin Transplants
Full-thickness skin was taken from the ears of AIB1/SRC-
3/ and / mice (donors) and was transplanted onto
the backs of AIB1/SRC-3/ and / mice (recipients),
respectively.36 On day 9 after grafting, the transplants
had healed and a 3-mm-diameter dermal biopsy punch
(Miltex Inc) was used to generate full-thickness skin
wounds through the grafted skin in anesthetized ani-
mals (3- to 4-month-old males), and they were left to
heal. Photographs of open wound areas at different
times after wounding were quantified using NIH Im-
ageJ software.
Data Analysis and Statistics
Experiments were performed three times unless noted
otherwise in the figure legend. GraphPad Prism version 5
(GraphPad Software Inc., La Jolla, CA) was used for
statistical analysis and for nonlinear regression analysis.
Analysis of variance was used for multiple comparisons
and t tests for paired comparisons. Statistical signifi-
cance was defined as P  0.05 unless stated otherwise.
Results
AIB1/SRC-3 Depletion Impairs Endothelial Cell
Function in Vitro
To assess the effect of AIB1/SRC-3 to modulate the ability
of endothelial cells to sprout in response to appropriate
cues, a tube formation assay in collagen was used.32
Depletion of AIB1/SRC-3 by shRNA silencing disrupted
the ability of endothelial cells (HUVECs) to form tubes
and reduced the average diameter of the tubes (Figure 1,A and B). Endothelial cells form the barrier layer between
the bloodstream and the parenchyma, and we, thus,
monitored the impact of AIB1/SRC-3 depletion on the
ability of endothelial cells to form monolayers with tight
junctions using electric cell-substrate impedance sens-
ing as described elsewhere.33,34 On AIB1/SRC-3 deple-
tion, endothelial monolayer resistance dropped by50%
(Figure 1C), suggesting a reduction in barrier function.
Beyond this steady-state barrier function of endothelial
cells, the repair of an endothelial monolayer in vitro can
be used to assess the potential effect on the repair of
endothelia in vivo. In an in vitro scratch assay, depletion
of AIB1/SRC-3 in endothelial cells resulted in a delay of
migration toward the denuded area compared with con-
trol cells (Figure 1, D and E) and an increased fraction of
cells undergoing reduced proliferation and apoptosis
(Figure 1, F and G; see also Supplemental Figure S2, A
and B, at http://ajp.amjpathol.org). This delay in scratch
closure was not due to lack of proliferation of the endo-
thelial cells since the same result was obtained in the
presence of mitomycin C (see Supplemental Figure S2, C
and D, at http://ajp.amjpathol.org). Moreover, the effects
we observed in endothelial cells are not due to shRNA
off-target effects since two distinct AIB1/SRC-3–targeted
shRNAs (Figure 1H) caused similar changes in pheno-
type. Taken together, these data suggest that AIB1/
SRC-3 is important for endothelial-specific functions that
include tube and monolayer formation.
To determine whether AIB1/SRC-3 showed a role in
other stromal cell types, we examined different fibroblast
cell lines. Proliferation of mouse or human fibroblasts was
unaffected by the depletion or overexpression of AIB1/
SRC-3 (see Supplemental Figure S3, A–D, at http://ajp.
amjpathol.org), although the motility of human fibroblasts
in a scratch assay was impaired by AIB1/SRC-3 loss (see
Supplemental Figure S3, E and F, at http://ajp.amjpathol.
org). These data suggest distinct roles of AIB1/SRC-3 in
different stromal cell types.
Role of AIB1/SRC-3 for Angiogenesis in Vivo
We previously observed that angiogenesis is reduced in
mammary tumors of mouse mammary tumor virus–HER2/
Neu mice when comparing AIB1/SRC-3/ and / ge-
notype mice, whereas / mice did not form tumors at
all.9 To investigate the effect of AIB1/SRC-3 genotype on
angiogenesis, we used a Matrigel plug assay. Matrigel is
placed subcutaneously, and neoangiogenesis can be
monitored by increased mRNA expression of endothelial
marker CD31 and loss of inflammatory marker CD14 in
the plug (see Supplemental Figure S4 at http://ajp.
amjpathol.org), without the influence of an epithelial com-
ponent. Histologic analysis and quantitation of the rela-
tive number of endothelial cells after a fixed time showed
that endothelial cell invasion into the plugs of AIB1/SRC-
3/ and / mice was significantly reduced compared
with that of / mice (Figure 2). The induction of angio-
genesis in this assay is driven by locally released growth
factors due to the subcutaneous wound caused by the
Matrigel injection. We next tested whether supplemen-
tation of the Matrigel plugs with an excess of FGF2
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different AIB1/SRC-3 genotypes. Addition of FGF2 in-
duced a significant, 5.5-fold angiogenic response in
AIB1/SRC-3/mice relative to baseline levels. However,
AIB1/SRC-3/ and / mice still showed significantly
reduced angiogenesis even with the added FGF2 (Figure
2). We conclude that the loss of AIB1/SRC-3 results in a
reduced capacity to mount an angiogenic response to a
subcutaneous injury that cannot be rescued by an ex-
cess of FGF2. Also, it seems that the loss of a single
AIB1/SRC-3 allele, ie, in / mice, reduces the angio-
genic response by 70% to 90% (Figure 2B).
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dothelial cell function in vitro. Endogenous
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images of repair of denuded endothelial mono-
layer areas by cell migration at 24 and 48 hours,
with the white line indicating the migration front
of cells. Scale bars: 0.1 mm. E: Quantitation of
the closure of the denuded area. Values are
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**P 0.001 versus control. F: Values are given as
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AJP April 2012, Vol. 180, No. 4AIB1/SRC-3/ and / mice showed a macroscopic
greater wound opening and a distinctly inflamed appear-
ance compared with / mice. The latter showed more
complete healing of the lesions with no evidence of re-
sidual inflammation (Figure 3A). Analysis of the digitized
images of the wound areas revealed a significant wound
closure delay in AIB1/SRC-3/ and / mice, with
mean  SEM wound openings of 5.4 1.3 and 4.9 0.9
mm2, respectively, versus 1.4  0.1 mm2 in / mice
(Figure 3, A and B). Measurement of the distance be-
tween the epithelial tips under the incisional injury scab
indicated that AIB1/SRC-3/ and / mice had signifi-
cantly reduced epithelial closure relative to / animals
(mean  SEM: 0.9  0.06 and 0.98  0.085 mm, respec-
tively, versus 0.57  0.03 mm; Figure 3, C and D). Stain-
ing for PCNA in the granulation tissue (Figure 3E) in the
hyperproliferative epithelium at the wound edge (see
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versus control. C: Representative H&E-stained sections of excisional skin wou
tongues. Scale bars: 0.2 mm. D: Quantitation of wound reepithelialization, a
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0.1 mm. F: Quantitation of the PCNA-positive nuclei. Proliferation index 
3 to 4 animals per group). *P  0.001, ***P  0.05 versus control. Macroscopi
areas in AIB1/SRC-3/ and / mice relative to day 0. Values are given asSupplemental Figure S5A at http://ajp.amjpathol.org)showed a significantly lower number of proliferating cells
of AIB1/SRC-3/ and / mice relative to / animals
(Figure 3F; see also Supplemental Figure S5B at http://
ajp.amjpathol.org). Note that AIB1/SRC-3 protein levels
measured by immunohistochemical analysis were re-
duced significantly in the healthy skin and granulation
tissue of AIB1/SRC-3/ mice relative to controls and
were not detectable in / mice (see Supplemental Fig-
ure S5C at http://ajp.amjpathol.org). Still, the extent of
defective wound healing in the AIB1/SRC-3/ and /
mice showed no significant difference (Figure 3, B, D,
and F), indicating that the loss of one AIB1/SRC-3 allele
was sufficient to maximally impede the wound-healing
response. Since homozygous AIB1/SRC-3/ mice have
reduced reproductive function and viability38 in contrast
to heterozygous AIB1/SRC-3/ mice, we used / mice
for further in-depth analyses of the wound-healing re-
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AJP April 2012, Vol. 180, No. 4control / littermates was observed over an 8-day pe-
riod (Figure 3G). Differences in wound closure became
apparent by day 4 after wounding and were sustained
throughout the healing process. In fact, day 8 wounds
from AIB1/SRC-3/mice exhibited almost complete clo-
sure, whereas those from / mice still showed a 40%
opening (Figure 3H). Histologic analysis revealed well-
progressing healing over time that was characterized by
mature granulation tissue, continuous wound contraction,
and reepithelialization in controls. This was accompanied
by the presence of superficial neutrophils at the base of
the scab, migrating and proliferating spindled fibro-
blasts and macrophages, gradual increase of infiltrat-
ing endothelial cells with subsequent neoangiogen-
esis, and collagen deposition from the base throughout
the whole wound area. The different healing features
are indicated in Supplemental Figure S5D (available at
http://ajp.amjpathol.org). In contrast, wounds from AIB1/
SRC-3/ mice showed a significantly slower healing
process with poorer wound contraction, delayed fibrin
breakdown, and very little collagen deposition. Immature
granulation tissue was mainly present at the periphery of
the wound, with fewer infiltrating cells and delayed neo-
angiogenesis (see Supplemental Figure S5D at http://
ajp.amjpathol.org).
Contribution of AIB1/SRC-3 to the Inflammatory
and Angiogenic Responses during Wound
Healing
The inflammatory response is characteristic of the early
phase of wound healing.39 Consistent with the notion of
rapid recruitment of inflammatory cells, such as mono-
cytes and macrophages, which express CD14 and
CD16markers, 1 day after wounding there was a300-
fold increase in CD14 expression and a 50-fold in-
crease in CD16 expression in the wounds of AIB1/SRC-
3/ mice compared with nonwounded skin (Figure 4A).
In contrast, increases in CD14 and CD16 levels in
wounds from AIB1/SRC-3/ mice were significantly
smaller than those from / mice. In day 4 wounds, the
levels of CD14 and CD16 decreased and were no longer
different between AIB1/SRC-3/ and / mice (Figure
4A). This finding suggests that the impact of AIB1/SRC-3
on inflammatory cell recruitment occurs during the initial
response to injury. This difference in inflammatory re-
sponse could be due to changes in the complement of
immune and endothelial progenitor cells in the bone mar-
row of the different AIB1/SRC-3 genotypes. However, the
expression levels of a diverse set of hematopoietic, mes-
enchymal stem cell, and proinflammatory markers
showed no significant differences between bone marrow
of AIB1/SRC-3/ and / mice (Figure 4B).
To directly assess the local contribution of the altered
AIB1/SRC-3 genotype, we transplanted skin from AIB1/
SRC-3/ and / mice onto / or / mice, respec-
tively. Within 2 weeks, these grafts healed-in, and full-
thickness excisional wounds were then generated in the
center of the grafts. Image analysis of the wounds was
used to assess the impact of the recipient and donorgenotype on wound closure (see Supplemental Figure S6
at http://ajp.amjpathol.org). Note that in this crossover
study, each host animal carried grafts from both donor
genotypes. It was striking that wounds in skin grafts
from AIB1/SRC-3/ donors healed significantly better
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Staining of granulation tissue of day 5 wounds for F4/80-positive macro-
phages (arrowheads). Scale bars: 0.1 mm. D: Number of F4/80-positive
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http://ajp.amjpathol.org).than did grafts from / donors irrespective of the
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AIB1/SRC-3 mostly affects locally acting drivers rather
than cells or soluble factors in the circulation of the
host or bone marrow cells induced and recruited dur-
ing wound healing.
Note that AIB1/SRC-3 mRNA levels in the wounds of
AIB1/SRC-3/ mice were up-regulated twofold 1 day
after wounding and returned to control levels after 4 days,
whereas no such changes were found in the wounds of
/ mice (see Supplemental Figure S7 at http://ajp.
amjpathol.org). AIB1 mRNA in the wounds of AIB1/SRC-
3/ mice were reduced by 80% relative to the peak
levels in / mice, and AIB1 protein levels in the wound
also corroborate this observation (see Supplemental Fig-
ure S5B at http://ajp.amjpathol.org). This might explain
why the delayed wound-healing response in the homozy-
gous AIB1/SRC-3/ mice and the heterozygous /
mice was indistinguishable (Figure 3, A–F). Consistent
with the impact of AIB1/SRC-3 silencing on the local
inflammatory response, wounds from AIB1/SRC-3/
mice showed a significant reduction by 55% in F4/80
staining of mature macrophages relative to / mice
(Figure 4, C and D), whereas the analysis of bone
marrow in / versus / mice did not show a differ-
ence in F4/80 levels (Figure 4B).
Another hallmark of wound healing and tissue remod-
eling is the production of MMPs predominantly by the
inflammatory cells and macrophages that promote extra-
cellular matrix breakdown.37,40 MMP activity is also a
feature of tissue remodeling during tumorigenesis.41 We,
therefore, examined, by in vivo imaging, the overall activ-
ity of MMPs (MMP-2, MMP-3, MMP-7, MMP-9, MMP-12,
and MMP-13) in the wounds by monitoring an MMP ac-
tivatable fluorescent substrate that was injected intrave-
nously. Peak levels of MMP activity were observed in
AIB1/SRC-3/ mice 3 days after wounding, with a con-
tinuous decrease until day 6 (Figure 4, E and F; see also
Supplemental Figure S8 at http://ajp.amjpathol.org). In
contrast, in AIB1/SRC-3/ mice, MMP activity did not
increase above the initial levels and progressively de-
creased. Also, at all time points, the MMP activity was
lower in AIB1/SRC-3/ than in / mice (see Supple-
mental Figure S8 at http://ajp.amjpathol.org). These find-
ings were corroborated by an expression survey of
wound-healing–related genes. A significant decrease in
MMP-9 mRNA expression in day 4 wounds of AIB1/SRC-
3/ versus / mice was observed (see Supplemental
Figure S9 at http://ajp.amjpathol.org). Altogether, these
data support the notion of compromised immune cell
infiltration and consequently slower extracellular matrix
remodeling by MMPs in wounds from AIB1/SRC-3/
mice as a contributing factor to the defective wound
healing seen at the macroscopic level. Consistent with a
direct effect of AIB1/SRC-3 on endothelial cell function,
the number of infiltrating capillaries in the wound granu-
lation tissue of AIB1/SRC-3/ mice was significantly re-
duced relative to that of /mice (Figure 5, A and B), and
this decrease in neoangiogenesis was consistent with a
reduction in VEGF-A immunoreactivity in the same tis-
sues (Figure 5, C and D).Driver Pathways of AIB1/SRC-3 Effects during
Wound Healing
To assess which signaling pathways are affected by
AIB1/SRC-3 during wound healing, we surveyed the ex-
pression of a set of known genes involved in wound
healing and angiogenesis. Overall, comparison of gene
expression patterns in wounds from AIB1/SRC-3/ ver-
sus / mice surveying 84 known angiogenic modulator
genes did not show significant changes greater than
twofold for most genes represented on the array, includ-
ing prominent angiogenic factors, such as FGF1 and
FGF2. Noteworthy examples of genes with differential
expression between wounds of AIB1/SRC-3/ and /
mice were the macrophage-derived cytokine CXCL2 and
HIF1- (see Supplemental Figure S9 at http://ajp.
amjpathol.org), with seven genes seeming to be up-reg-
ulated more than fourfold. Since AIB1/SRC-3 knockout
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other vertebrates, lack the FGFBP2 gene.43,44mice failed to fully respond to FGF2 stimulation in the
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naling molecules could be likely drivers of the differential
wound-healing response of AIB1/SRC-3/ versus /
mice. Also, in an earlier work we had found that AIB1
affects transcription of a secreted FGF-binding protein
(FGFBP1)42 that can control angiogenesis,43,44 wound
healing,35,45 and vascular permeability.46 We also as-
sessed mRNA expression of FGF7, FGF10, FGF recep-
tors (FGFR1-4), FGFBP1, and FGFBP347–49 in 4-day
wounds. Wounds from AIB1/SRC-3/ mice showed sig-
nificantly lower expression of FGF10, FGFBP3, FGFR1,
and FGFR3 compared with / controls (Figure 5E).43,44
Also, the expression ratio of FGFR2b to c splice isoforms
was changed in favor of the b-isoform in wounds from
AIB1/SRC-3/ mice, whereas the FGFR1 and FGFR3
isoform ratios were not affected (see Supplemental Fig-
ure S10 at http://ajp.amjpathol.org). FGF10 preferentially
signals through FGFR2b,50 and the impact of the in-
creased FGF10 expression in the wounds of AIB1/SRC-
3/ mice will, thus, be enhanced together with a differ-
ence in overall levels of FGFR1 and FGFR3 in favor of
wounds from / mice. The phenotypic effects of AIB1/
SRC-3 reduction were also reflected in distinct changes
in FGF2-induced signal transduction in endothelial cells
in vitro. The induction of phospho–mitogen-activated pro-
tein kinase by exogenously added FGF2 was unchanged
after AIB1/SRC-3 knockdown, whereas phospho-AKT
and phospho-p38 induction were reduced (see Supple-
mental Figure S11 at http://ajp.amjpathol.org). Thus, the
loss of AIB1 in endothelial cells in vitro seems to affect
signal transduction hubs downstream of the FGF recep-
tor pathway. Altogether, these findings indicate that the
loss of AIB1/SRC-3 negatively affects key drivers of
wound healing along the FGF pathway.
Discussion
We show herein a previously unknown function of AIB1/
SRC-3 in the control of endothelial cell phenotypes in vitro
and neoangiogenesis and physiologic wound healing in
vivo. Previous reports have focused predominantly on the
role of this nuclear receptor coactivator in epithelial cells
and have shown overexpression in a variety of cancer
epithelia, including breast, prostate, colon, pancreas,
and lung.1,11–15 As reported earlier, reduction of AIB1/
SRC-3 in epithelial cells inhibits responses to corticoste-
roid hormones, insulinlike growth factor 1, epidermal
growth factor, and heregulin.10,19 These pleiotropic ef-
fects are not surprising given that AIB1/SRC-3 is not only
a coactivator of nuclear receptors but also a coactivator
of a diverse group of other transcription factors.51 We
now show that the loss of AIB1/SRC-3 in endothelial cells
affects a range of endothelial-specific phenotypes, in-
cluding formation of intact monolayers and tubes. Also,
these in vitro observations suggest that the reduced neo-
angiogenesis in the Matrigel assay and during wound
healing are likely due to altered endothelial cell response.
This notion is supported by the data in the Matrigel neo-
angiogenesis experiments in AIB1/SRC-3/ and /mice where exogenously added FGF2 was not able torescue the angiogenic response in these animals. Note,
however, that despite these defects in neoangiogenesis
and tissue repair in adult animals described herein, AIB1/
SRC-3/ mice are viable at birth and have no discern-
ible vascular phenotype. However, fertility and the num-
ber of offspring per birth are low. This could be due to
poor uterine implantation of embryos that requires inva-
sion into the uterine lining and the recruitment of uterine
blood vessels.6,38 AIB1 is known to affect epithelial pro-
liferation, and we observed a reduced number of prolif-
erating keratinocytes in the wounds in AIB1/SRC-3/
mice (see Supplemental Figure S5, A and B, at http://
ajp.amjpathol.org). This reduced epithelial proliferation
could indirectly affect stromal cell function and provide a
further mechanism of reduced wound closure and de-
layed reepithelialization.
Surprising to us was the fact that the wound-healing
response is already maximally affected in heterozygous
AIB1/SRC-3/ mice and is not further affected by a
complete loss of the AIB1/SRC-3 gene. Whereas wounds
on AIB1/SRC-3/ mice showed no differential expres-
sion of AIB1/SRC-3 mRNA over time, steady-state AIB1/
SRC-3 mRNA was up-regulated in wounds of AIB1/SRC-
3/ mice, resulting in a fivefold expression difference at
peak levels during healing. This finding suggests positive
feedback of AIB1/SRC-3 expression in the injury site and
a threshold expression level needed to engage physio-
logic repair processes in the adult. On the other hand,
up-regulation of AIB1/SRC-3 in breast cancer stroma
(see Supplemental Figure S1 at http://ajp.amjpathol.org)
may reflect a wound-healing stromal response given that
there are overlapping pathways between cancer and
healing wounds,24,25 and an activated wound response
signature indicates poor outcome in breast cancers.52
Since loss of one AIB1/SRC-3 allele delays the develop-
ment of mouse mammary tumor virus–HER2/Neu–in-
duced tumors,9 it is tempting to speculate that similar
threshold mechanisms seen in wound healing are in-
volved in limiting the tumorigenesis, possibly due to the
reduced AIB1/SRC-3 in the tumor stroma.
The dampened response of wounds in AIB1/SRC-3/
mice was evident at different levels, including histologic
findings, gene expression level, and overall metallopro-
tease activity. This was accompanied by reduced recruit-
ment of inflammatory cells, such as macrophages and
monocytes, to the healing wound site evidenced by the
smaller rise in CD14 and CD16 inflammatory cell markers
and cytokines IL-1 and CXCL2 that are produced by
inflammatory cells in wounds.
Results of the functional and expression analysis sug-
gest that major drivers in the FGF pathway53 require
AIB1/SRC-3 to modulate neoangiogenesis and wound
healing. FGFR1 and FGFR3 and the FGFR2b ligand
FGF1050 were significantly reduced in the wounds of
AIB1/SRC-3/ animals relative to / controls. FGF7
and FGF10 are known to be involved in wound reepithe-
lialization and angiogenesis37 and are typically produced
by stromal cells to act predominantly on the epithelial cell
FGFR2b isoform.50 The relative expression of the
FGFR2b isoform was significantly lower in the wounds of
AIB1/SRC-3/ mice, making this a further indicator and
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change in the comparison of wounds from AIB1/SRC-
3/ and control mice was the 16-fold difference in ex-
pression of the secreted FGFBP3 (Figure 5E). This se-
creted FGF-binding protein was shown earlier to interact
with FGF1 and FGF2 and to potentiate FGF2-dependent
vascular permeability and angiogenesis.46,49 Of note is
that FGF pathway genes monitored in the wound-healing
studies and those reported to be expressed in breast
cancer stroma showed parallel changes (see Supple-
mental Table S1 at http://ajp.amjpathol.org20), suggesting
these as common targets of AIB1/SRC-3 in the stromal
compartment and shared drivers of healing wounds and
malignancies proposed much earlier.24
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